Skip to main content

Advertisement

SpringerLink
Log in

Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aim was to retrospectively estimate the prevalence of calcinosis in patients with juvenile dermatomyositis (JDM) and to identify risk factors associated with development of calcinosis in these patients. Retrospective chart review of 39 children diagnosed with JDM between 2004 and 2015 in a tertiary care hospital was done. Patients were divided into two groups, depending on the presence or absence of calcinosis, and the two groups were compared with respect to demographic, clinical, laboratory and therapeutic characteristics. Calcinosis developed in nine (23.1 %) patients. Delay in diagnosis and initiation of treatment, prolonged duration of disease, the presence of joint contractures and cardiac involvement were significantly associated with increased frequency of calcinosis. Six out of nine (66.7 %) patients with calcinosis received alendronate therapy, out of which four showed partial reduction in calcinosis. In one case, surgical removal of tumorous clumps was done. Calcinosis remains a common complication of JDM. We found an association between calcinosis and delay in diagnosis and initiation of treatment, prolonged duration of disease and cardiac involvement. Our study suggests that alendronate may be beneficial in management of calcinosis of JDM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rider LG, Lindsley CB, Cassidy JT (2005) Juvenile dermatomyositis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology, 6th edn. Elsevier Saunders, Philadelphia, pp 375–413

    Google Scholar 

  2. Huber A, Feldman BM (2005) Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? Curr Rheumatol Rep 7:441–446

    Article  PubMed  Google Scholar 

  3. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S (2012) Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 41:50–58

    Article  CAS  PubMed  Google Scholar 

  4. Sanner H, Gran JT, Sjaastad I, Flato B (2009) Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 48:1541–1547

    Article  Google Scholar 

  5. Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldmen BM et al (2009) Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 60:3425–3435

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res 62:63–72

    Article  Google Scholar 

  7. Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM et al (2009) A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol 27:1031–1038

    CAS  PubMed  Google Scholar 

  8. Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N et al (2011) Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol 29:117–124

    PubMed  Google Scholar 

  9. Efthimiou P, Kukar M, Kagen LJ (2010) Images in rheumatology. Severe adult-onset calcinosis in a patient with a history of juvenile dermatomyositis. J Rheumatol 37:194

    Article  PubMed  Google Scholar 

  10. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT (1983) Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 103:882–888

    Article  CAS  PubMed  Google Scholar 

  11. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344–347

    Article  CAS  PubMed  Google Scholar 

  12. Mukamel M, Horev G, Mimouni M (2001) New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 138:763–766

    Article  CAS  PubMed  Google Scholar 

  13. Pachman LM, Boskey AL (2006) Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep 8:236–243

    Article  CAS  PubMed  Google Scholar 

  14. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP (2002) Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47:505–511

    Article  PubMed  Google Scholar 

  15. Pachman LM, Maryjowski MC (1984) Juvenile dermatomyositis and polymyositis. Clin Rheum Dis 10:95–115

    CAS  PubMed  Google Scholar 

  16. Ramanan AV, Feldman BM (2002) Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 28:833–857

    Article  CAS  PubMed  Google Scholar 

  17. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P et al (2000) Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 43:541–549

    Article  CAS  PubMed  Google Scholar 

  18. Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterized by frequent dystrophic calcification: a cross sectional study. Pediatr Rheumatol 12:2

    Article  Google Scholar 

  19. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D (2014) Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 150:724–729

    Article  PubMed  PubMed Central  Google Scholar 

  20. Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R (1994) Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis. Arthritis Rheum 37:R10A

    Article  Google Scholar 

  21. Sallum AM, Pivato FC, Doria-Filho U, Aikawa NE, Liphaus BL, Marie SK et al (2008) Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 84:68–74

    Article  Google Scholar 

  22. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668–1678

    Article  CAS  PubMed  Google Scholar 

  23. Van Gelder JM, Breuer E, Ornoy A, Schlossman A, Patlas N, Golomb G (1995) Anticalcification and antiresorption effects of bisacylphosphonates. Bone 16:511–520

    Article  PubMed  Google Scholar 

  24. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A (2010) Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine 77:70–72

    Article  PubMed  Google Scholar 

  25. Marco Puche A, Calvo PI, Lopez MB (2010) Effectiveness of treatment with intravenous pamidronate for calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol 28:135–140

    CAS  PubMed  Google Scholar 

  26. Ambler GR, Chaitow J, Rogers M, McDonald D, Ouvrier RA (2005) Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol 32:1837–1839

    PubMed  Google Scholar 

Download references

Author contributions

IS contributed to data collection, analysis and manuscript writing; SKK contributed to data collection, analysis, manuscript writing and was a guarantor for the study; and MK analyzed data and wrote manuscript.

Author information

Authors and Affiliations

  1. Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India

    Isha Saini & Sushil Kumar Kabra

  2. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 110029, India

    Mani Kalaivani

Authors
  1. Isha Saini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mani Kalaivani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sushil Kumar Kabra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sushil Kumar Kabra.

Ethics declarations

Conflict of interest

Author Isha Saini declares that she has no conflict of interest. Author Mani Kalaivani declares that she has no conflict of interest, and author Sushil Kumar Kabra declares that he has no conflict of interest.

Ethical approval

Not required as it was retrospective chart review and none of the patients enrolled in study have been identified by name.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saini, I., Kalaivani, M. & Kabra, S.K. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int 36, 961–965 (2016). https://doi.org/10.1007/s00296-016-3467-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3467-6

Keywords

Search

Navigation